PHARMACOECONOMIC EVALUATION IN PATIENTS HAVING MYOCARDIAL INFRACTION WITH HYPERTENSION IN THE GOVERNMENT TERTIARY CARE HOSPITAL

Sunadraj M. S., Steffy Anna George, Tejaswini M. and Sasidhar Joga*

ABSTRACT

The present review has been done to identifying, measuring and comparing the costs and benefits of programs, services or therapies and determining which alternative produces the best health outcome for the resource invested. All methods of pharmacoeconomic evaluation share the common feature of comparing inputs (cost) with outcomes (benefits) resulting from drug intervention in myocardial infraction with hypertension patients. To document the various treatments that the patients are receiving in MIMS, Mandya for hypertension and myocardial infraction. To record the expenses involved in different treatments. To apply cost effectiveness analysis and determine which of the treatments for myocardial infraction with hypertension. A cross sectional descriptive study conducted on hypertension with MI patients in the general medicine department of MIMS. The 6 months study was conducted on 200 patients. Of the total study population 58% was male, and 42% was female patients. The age group of patients were observed as 61-70years. Out of 200 patients, 70 (35%) patients had hypertension, 35 (17.5%) patients had MI, and 90 (47.5%) patients had both hypertension with MI. In monotherapy only labetalol showed a significant reduction of SBP values after 6 months. The other two groups of drugs telmisartan and cilnidipine showed reduction of both SBP at end of 3rd and 6th month and, but that reductions were not significant at any stages. In combination therapy, A significant reduction in SBP was achieved in the treatment with torsemide + spironolactone after 6th month. The reductions of SBP of the other two groups of combination were not significant. The 6 months study shows that labetalol is comparatively cost-effective in the reduction of per mmHg of SBP. In case of combination therapy, telmisartan and amlodipine are comparatively cost-effective in the reduction of per mmHg of SBP in hypertension with myocardial infraction patients.

Keywords: MI, hypertension, cost effectiveness.